Alterations of leptin during IFN-α therapy in patients with chronic viral hepatitis
Leptin has a particular profibrogenic role in the liver. We investigated whether IFN-α influences leptin production in patients with chronic hepatitis B (CHB) and C (CHC). Leptin was determined in serial samples from 63 CHB and 42 CHC IFN-α treated patients. Furthermore, we evaluated whether leptin...
Gespeichert in:
| Veröffentlicht in: | Journal of hepatology 2006-05, Vol.44 (5), p.848-855 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 855 |
|---|---|
| container_issue | 5 |
| container_start_page | 848 |
| container_title | Journal of hepatology |
| container_volume | 44 |
| creator | Zografos, Theodoros A. Rigopoulou, Eirini I. Liaskos, Christos Togousidis, Elias Zachou, Kalliopi Gatselis, Nikolaos Germenis, Anastasios Dalekos, George N. |
| description | Leptin has a particular profibrogenic role in the liver. We investigated whether IFN-α influences leptin production in patients with chronic hepatitis B (CHB) and C (CHC). Leptin was determined in serial samples from 63 CHB and 42 CHC IFN-α treated patients. Furthermore, we evaluated whether leptin alterations were associated with patients' characteristics.
Sera were investigated at serial time-points using an enzyme-linked-immunosorbent-assay. Controls consisted of 36 patients with autoimmune liver diseases and 44 healthy patients.
Leptin levels before IFN-α administration were higher in CHB and CHC compared to healthy (
P |
| doi_str_mv | 10.1016/j.jhep.2006.01.025 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67870859</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0168827806000705</els_id><sourcerecordid>67870859</sourcerecordid><originalsourceid>FETCH-LOGICAL-c384t-ea16779e2f17431e4377d5d4b3e1f0850f30a8d905b10beb3b1e57b7ee82f6f53</originalsourceid><addsrcrecordid>eNp9kE1OwzAQRi0EglK4AAvkDewSxnESJxIbhPiTKtjA2nKcMXWVJsF2izgWF-FMuGoldqxmMe_7ZvQIOWOQMmDl1SJdzHFMM4AyBZZCVuyRCSsBEihztk8mEaqSKhPVETn2fgEAHOr8kByxsuCQ1TAhrzddQKeCHXpPB0M7HIPtabtytn-nT_fPyc83DfOIjF80LsaIYh88_bRhTvXcDb3VdG2d6mh8Jm6D9SfkwKjO4-luTsnb_d3r7WMye3l4ur2ZJZpXeUhQsVKIGjPDRM4Z5lyItmjzhiMzUBVgOKiqraFoGDTY8IZhIRqBWGWmNAWfkstt7-iGjxX6IJfWa-w61eOw8rIUlYg9dQSzLajd4L1DI0dnl8p9SQZy41Iu5Mal3LiUwGR0GUPnu_ZVs8T2L7KTF4GLHaC8Vp1xqtfW_3Fic5yJyF1vOYwu1had9DpK1NhahzrIdrD__fELsVWTDw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67870859</pqid></control><display><type>article</type><title>Alterations of leptin during IFN-α therapy in patients with chronic viral hepatitis</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Zografos, Theodoros A. ; Rigopoulou, Eirini I. ; Liaskos, Christos ; Togousidis, Elias ; Zachou, Kalliopi ; Gatselis, Nikolaos ; Germenis, Anastasios ; Dalekos, George N.</creator><creatorcontrib>Zografos, Theodoros A. ; Rigopoulou, Eirini I. ; Liaskos, Christos ; Togousidis, Elias ; Zachou, Kalliopi ; Gatselis, Nikolaos ; Germenis, Anastasios ; Dalekos, George N.</creatorcontrib><description>Leptin has a particular profibrogenic role in the liver. We investigated whether IFN-α influences leptin production in patients with chronic hepatitis B (CHB) and C (CHC). Leptin was determined in serial samples from 63 CHB and 42 CHC IFN-α treated patients. Furthermore, we evaluated whether leptin alterations were associated with patients' characteristics.
Sera were investigated at serial time-points using an enzyme-linked-immunosorbent-assay. Controls consisted of 36 patients with autoimmune liver diseases and 44 healthy patients.
Leptin levels before IFN-α administration were higher in CHB and CHC compared to healthy (
P<0.004) and diseased controls (
P=0.0001). In CHB patients, we observed a significant reduction of leptin during IFN-α treatment and lasting for up to 6 months after the end of treatment, followed by an increase reaching pretreatment levels at 1.5 years after stopping therapy. The pattern of leptin alterations was similar in CHC patients where leptin's decrease was more pronounced at 6 months after the end of treatment. Biochemical or virological response to treatment was not associated with leptin reduction in both groups.
This study provides information on leptin kinetics during IFN-α treatment and follow-up in CHB and CHC patients and suggests IFN-α as a potential inhibitor of leptin production.</description><identifier>ISSN: 0168-8278</identifier><identifier>EISSN: 1600-0641</identifier><identifier>DOI: 10.1016/j.jhep.2006.01.025</identifier><identifier>PMID: 16530290</identifier><identifier>CODEN: JOHEEC</identifier><language>eng</language><publisher>Oxford: Elsevier B.V</publisher><subject>Adult ; Aged ; Antiviral Agents - administration & dosage ; Biological and medical sciences ; Chronic hepatitis B ; Chronic hepatitis C ; Cirrhosis ; Female ; Follow-Up Studies ; Gastroenterology. Liver. Pancreas. Abdomen ; Hepatitis B, Chronic - blood ; Hepatitis B, Chronic - drug therapy ; Hepatitis C, Chronic - blood ; Hepatitis C, Chronic - drug therapy ; Hepatitis, Autoimmune - blood ; Hepatitis, Autoimmune - drug therapy ; Human viral diseases ; Humans ; Infectious diseases ; Interferon-alpha - administration & dosage ; Interferon-α ; Leptin ; Leptin - antagonists & inhibitors ; Leptin - blood ; Liver Cirrhosis - blood ; Liver Cirrhosis - drug therapy ; Liver Cirrhosis - immunology ; Liver fibrosis ; Liver. Biliary tract. Portal circulation. Exocrine pancreas ; Male ; Medical sciences ; Middle Aged ; Other diseases. Semiology ; Prospective Studies ; Sex Characteristics ; Treatment Outcome ; Viral diseases ; Viral hepatitis</subject><ispartof>Journal of hepatology, 2006-05, Vol.44 (5), p.848-855</ispartof><rights>2006 European Association for the Study of the Liver</rights><rights>2006 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c384t-ea16779e2f17431e4377d5d4b3e1f0850f30a8d905b10beb3b1e57b7ee82f6f53</citedby><cites>FETCH-LOGICAL-c384t-ea16779e2f17431e4377d5d4b3e1f0850f30a8d905b10beb3b1e57b7ee82f6f53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jhep.2006.01.025$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17708517$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16530290$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zografos, Theodoros A.</creatorcontrib><creatorcontrib>Rigopoulou, Eirini I.</creatorcontrib><creatorcontrib>Liaskos, Christos</creatorcontrib><creatorcontrib>Togousidis, Elias</creatorcontrib><creatorcontrib>Zachou, Kalliopi</creatorcontrib><creatorcontrib>Gatselis, Nikolaos</creatorcontrib><creatorcontrib>Germenis, Anastasios</creatorcontrib><creatorcontrib>Dalekos, George N.</creatorcontrib><title>Alterations of leptin during IFN-α therapy in patients with chronic viral hepatitis</title><title>Journal of hepatology</title><addtitle>J Hepatol</addtitle><description>Leptin has a particular profibrogenic role in the liver. We investigated whether IFN-α influences leptin production in patients with chronic hepatitis B (CHB) and C (CHC). Leptin was determined in serial samples from 63 CHB and 42 CHC IFN-α treated patients. Furthermore, we evaluated whether leptin alterations were associated with patients' characteristics.
Sera were investigated at serial time-points using an enzyme-linked-immunosorbent-assay. Controls consisted of 36 patients with autoimmune liver diseases and 44 healthy patients.
Leptin levels before IFN-α administration were higher in CHB and CHC compared to healthy (
P<0.004) and diseased controls (
P=0.0001). In CHB patients, we observed a significant reduction of leptin during IFN-α treatment and lasting for up to 6 months after the end of treatment, followed by an increase reaching pretreatment levels at 1.5 years after stopping therapy. The pattern of leptin alterations was similar in CHC patients where leptin's decrease was more pronounced at 6 months after the end of treatment. Biochemical or virological response to treatment was not associated with leptin reduction in both groups.
This study provides information on leptin kinetics during IFN-α treatment and follow-up in CHB and CHC patients and suggests IFN-α as a potential inhibitor of leptin production.</description><subject>Adult</subject><subject>Aged</subject><subject>Antiviral Agents - administration & dosage</subject><subject>Biological and medical sciences</subject><subject>Chronic hepatitis B</subject><subject>Chronic hepatitis C</subject><subject>Cirrhosis</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Hepatitis B, Chronic - blood</subject><subject>Hepatitis B, Chronic - drug therapy</subject><subject>Hepatitis C, Chronic - blood</subject><subject>Hepatitis C, Chronic - drug therapy</subject><subject>Hepatitis, Autoimmune - blood</subject><subject>Hepatitis, Autoimmune - drug therapy</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Interferon-alpha - administration & dosage</subject><subject>Interferon-α</subject><subject>Leptin</subject><subject>Leptin - antagonists & inhibitors</subject><subject>Leptin - blood</subject><subject>Liver Cirrhosis - blood</subject><subject>Liver Cirrhosis - drug therapy</subject><subject>Liver Cirrhosis - immunology</subject><subject>Liver fibrosis</subject><subject>Liver. Biliary tract. Portal circulation. Exocrine pancreas</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Other diseases. Semiology</subject><subject>Prospective Studies</subject><subject>Sex Characteristics</subject><subject>Treatment Outcome</subject><subject>Viral diseases</subject><subject>Viral hepatitis</subject><issn>0168-8278</issn><issn>1600-0641</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1OwzAQRi0EglK4AAvkDewSxnESJxIbhPiTKtjA2nKcMXWVJsF2izgWF-FMuGoldqxmMe_7ZvQIOWOQMmDl1SJdzHFMM4AyBZZCVuyRCSsBEihztk8mEaqSKhPVETn2fgEAHOr8kByxsuCQ1TAhrzddQKeCHXpPB0M7HIPtabtytn-nT_fPyc83DfOIjF80LsaIYh88_bRhTvXcDb3VdG2d6mh8Jm6D9SfkwKjO4-luTsnb_d3r7WMye3l4ur2ZJZpXeUhQsVKIGjPDRM4Z5lyItmjzhiMzUBVgOKiqraFoGDTY8IZhIRqBWGWmNAWfkstt7-iGjxX6IJfWa-w61eOw8rIUlYg9dQSzLajd4L1DI0dnl8p9SQZy41Iu5Mal3LiUwGR0GUPnu_ZVs8T2L7KTF4GLHaC8Vp1xqtfW_3Fic5yJyF1vOYwu1had9DpK1NhahzrIdrD__fELsVWTDw</recordid><startdate>20060501</startdate><enddate>20060501</enddate><creator>Zografos, Theodoros A.</creator><creator>Rigopoulou, Eirini I.</creator><creator>Liaskos, Christos</creator><creator>Togousidis, Elias</creator><creator>Zachou, Kalliopi</creator><creator>Gatselis, Nikolaos</creator><creator>Germenis, Anastasios</creator><creator>Dalekos, George N.</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20060501</creationdate><title>Alterations of leptin during IFN-α therapy in patients with chronic viral hepatitis</title><author>Zografos, Theodoros A. ; Rigopoulou, Eirini I. ; Liaskos, Christos ; Togousidis, Elias ; Zachou, Kalliopi ; Gatselis, Nikolaos ; Germenis, Anastasios ; Dalekos, George N.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c384t-ea16779e2f17431e4377d5d4b3e1f0850f30a8d905b10beb3b1e57b7ee82f6f53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antiviral Agents - administration & dosage</topic><topic>Biological and medical sciences</topic><topic>Chronic hepatitis B</topic><topic>Chronic hepatitis C</topic><topic>Cirrhosis</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Hepatitis B, Chronic - blood</topic><topic>Hepatitis B, Chronic - drug therapy</topic><topic>Hepatitis C, Chronic - blood</topic><topic>Hepatitis C, Chronic - drug therapy</topic><topic>Hepatitis, Autoimmune - blood</topic><topic>Hepatitis, Autoimmune - drug therapy</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Interferon-alpha - administration & dosage</topic><topic>Interferon-α</topic><topic>Leptin</topic><topic>Leptin - antagonists & inhibitors</topic><topic>Leptin - blood</topic><topic>Liver Cirrhosis - blood</topic><topic>Liver Cirrhosis - drug therapy</topic><topic>Liver Cirrhosis - immunology</topic><topic>Liver fibrosis</topic><topic>Liver. Biliary tract. Portal circulation. Exocrine pancreas</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Other diseases. Semiology</topic><topic>Prospective Studies</topic><topic>Sex Characteristics</topic><topic>Treatment Outcome</topic><topic>Viral diseases</topic><topic>Viral hepatitis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zografos, Theodoros A.</creatorcontrib><creatorcontrib>Rigopoulou, Eirini I.</creatorcontrib><creatorcontrib>Liaskos, Christos</creatorcontrib><creatorcontrib>Togousidis, Elias</creatorcontrib><creatorcontrib>Zachou, Kalliopi</creatorcontrib><creatorcontrib>Gatselis, Nikolaos</creatorcontrib><creatorcontrib>Germenis, Anastasios</creatorcontrib><creatorcontrib>Dalekos, George N.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of hepatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zografos, Theodoros A.</au><au>Rigopoulou, Eirini I.</au><au>Liaskos, Christos</au><au>Togousidis, Elias</au><au>Zachou, Kalliopi</au><au>Gatselis, Nikolaos</au><au>Germenis, Anastasios</au><au>Dalekos, George N.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Alterations of leptin during IFN-α therapy in patients with chronic viral hepatitis</atitle><jtitle>Journal of hepatology</jtitle><addtitle>J Hepatol</addtitle><date>2006-05-01</date><risdate>2006</risdate><volume>44</volume><issue>5</issue><spage>848</spage><epage>855</epage><pages>848-855</pages><issn>0168-8278</issn><eissn>1600-0641</eissn><coden>JOHEEC</coden><abstract>Leptin has a particular profibrogenic role in the liver. We investigated whether IFN-α influences leptin production in patients with chronic hepatitis B (CHB) and C (CHC). Leptin was determined in serial samples from 63 CHB and 42 CHC IFN-α treated patients. Furthermore, we evaluated whether leptin alterations were associated with patients' characteristics.
Sera were investigated at serial time-points using an enzyme-linked-immunosorbent-assay. Controls consisted of 36 patients with autoimmune liver diseases and 44 healthy patients.
Leptin levels before IFN-α administration were higher in CHB and CHC compared to healthy (
P<0.004) and diseased controls (
P=0.0001). In CHB patients, we observed a significant reduction of leptin during IFN-α treatment and lasting for up to 6 months after the end of treatment, followed by an increase reaching pretreatment levels at 1.5 years after stopping therapy. The pattern of leptin alterations was similar in CHC patients where leptin's decrease was more pronounced at 6 months after the end of treatment. Biochemical or virological response to treatment was not associated with leptin reduction in both groups.
This study provides information on leptin kinetics during IFN-α treatment and follow-up in CHB and CHC patients and suggests IFN-α as a potential inhibitor of leptin production.</abstract><cop>Oxford</cop><pub>Elsevier B.V</pub><pmid>16530290</pmid><doi>10.1016/j.jhep.2006.01.025</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0168-8278 |
| ispartof | Journal of hepatology, 2006-05, Vol.44 (5), p.848-855 |
| issn | 0168-8278 1600-0641 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67870859 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Adult Aged Antiviral Agents - administration & dosage Biological and medical sciences Chronic hepatitis B Chronic hepatitis C Cirrhosis Female Follow-Up Studies Gastroenterology. Liver. Pancreas. Abdomen Hepatitis B, Chronic - blood Hepatitis B, Chronic - drug therapy Hepatitis C, Chronic - blood Hepatitis C, Chronic - drug therapy Hepatitis, Autoimmune - blood Hepatitis, Autoimmune - drug therapy Human viral diseases Humans Infectious diseases Interferon-alpha - administration & dosage Interferon-α Leptin Leptin - antagonists & inhibitors Leptin - blood Liver Cirrhosis - blood Liver Cirrhosis - drug therapy Liver Cirrhosis - immunology Liver fibrosis Liver. Biliary tract. Portal circulation. Exocrine pancreas Male Medical sciences Middle Aged Other diseases. Semiology Prospective Studies Sex Characteristics Treatment Outcome Viral diseases Viral hepatitis |
| title | Alterations of leptin during IFN-α therapy in patients with chronic viral hepatitis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T13%3A26%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Alterations%20of%20leptin%20during%20IFN-%CE%B1%20therapy%20in%20patients%20with%20chronic%20viral%20hepatitis&rft.jtitle=Journal%20of%20hepatology&rft.au=Zografos,%20Theodoros%20A.&rft.date=2006-05-01&rft.volume=44&rft.issue=5&rft.spage=848&rft.epage=855&rft.pages=848-855&rft.issn=0168-8278&rft.eissn=1600-0641&rft.coden=JOHEEC&rft_id=info:doi/10.1016/j.jhep.2006.01.025&rft_dat=%3Cproquest_cross%3E67870859%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67870859&rft_id=info:pmid/16530290&rft_els_id=S0168827806000705&rfr_iscdi=true |